financetom
Business
financetom
/
Business
/
Abercrombie & Fitch Insider Sold Shares Worth $2,501,264, According to a Recent SEC Filing
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Abercrombie & Fitch Insider Sold Shares Worth $2,501,264, According to a Recent SEC Filing
Sep 11, 2024 4:11 AM

05:10 PM EDT, 09/10/2024 (MT Newswires) -- Samir Desai, Executive Vice President, Chief Digital & Technology Officer, on September 06, 2024, sold 19,041 shares in Abercrombie & Fitch ( ANF ) for $2,501,264. Following the Form 4 filing with the SEC, Desai has control over a total of 27,985 shares of the company, with 27,985 shares held directly.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/1018840/000122520824008578/xslF345X05/doc4.xml

Price: 130.02, Change: +0.16, Percent Change: +0.12

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
CervoMed Q3 net loss widens
CervoMed Q3 net loss widens
Nov 10, 2025
Overview * CervoMed Q3 2025 net loss of $7.7 mln misses analyst expectations * Cash position decreased to $27.3 mln as of September 30, 2025 Outlook * CervoMed plans to initiate a global pivotal Phase 3 trial in DLB in H2 2026 * Company expects initial biomarker data from Phase 2a FTD trial in 2026 * CervoMed ( CRVO )...
Property developer Howard Hughes raises 2025 cash flow forecast by $30 mln
Property developer Howard Hughes raises 2025 cash flow forecast by $30 mln
Nov 10, 2025
Overview * Howard Hughes Q3 net income per share rises to $2.02 from $1.95 yr/yr * Company raises full-year 2025 adjusted operating cash flow guidance by $30 mln * Howard Hughes contracts $1.4 bln in future condo sales revenue Outlook * Howard Hughes raises full-year 2025 Adjusted Operating Cash Flow guidance to $440 mln * Company increases full-year 2025 MPC...
Israel's Tower Semiconductor edges past Q3 revenue estimates
Israel's Tower Semiconductor edges past Q3 revenue estimates
Nov 10, 2025
Overview * Tower Semiconductor Q3 2025 rev grows 6% qtr/qtr, slightly beating analyst expectations * Company expects 14% year-over-year revenue growth in Q4 2025 Outlook * Tower Semiconductor guides Q4 2025 revenue to $440 mln, plus or minus 5% * Tower Semiconductor invests $300 mln in SiPho and SiGe capacity expansion Result Drivers * CORE TECHNOLOGIES - Revenue growth driven...
Vera Therapeutics Submits Kidney Disease Therapy Biologics License Application to FDA; Shares Up Pre-Bell
Vera Therapeutics Submits Kidney Disease Therapy Biologics License Application to FDA; Shares Up Pre-Bell
Nov 10, 2025
07:09 AM EST, 11/10/2025 (MT Newswires) -- Vera Therapeutics ( VERA ) said late Friday it submitted a biologics license application to the US Food and Drug Administration through an accelerated approval program for atacicept to treat adults with immunoglobulin A nephropathy, or IgAN. The submission is based on a prespecified interim analysis of the phase 3 trial, which met...
Copyright 2023-2026 - www.financetom.com All Rights Reserved